IGeneX Broad Coverage Ab Lyme Disease, Tick-Borne Relapsing Fever Assays
IGeneX has launched two assays for the pathogens that can cause Lyme disease and tick-borne relapsing fever. The tests use the firm's Broad Coverage Ab (BCA) technology to detect both IgM and IgG antibodies against multiple species and strains of Lyme Borreliae and TBRF Borreliae in blood serum. They can detect species and strains native to North America, Europe and Australia, and the firm said they are simpler and more cost-effective than standard two-tier testing using ELISA. The testing is offered as a service from the firm's Milpitas, California lab at a cost of $195 per test, with physicians required collect test specimens using IGeneX collection kits.